# Vanda Sets $240 Million-Plus 2026 Revenue Goal, Plans Q4 BYSANTI Launch

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/43294
Published: 2026-10-29T07:24:13.000Z
Updated: 2026-10-29T07:24:13.000Z
Section: Business

> Vanda’s third-quarter revenue increased 24% year over year.

Vanda Pharmaceuticals Inc. said it is targeting more than $240 million in revenue for 2026 and plans to launch BYSANTI in the fourth quarter.

Management linked the third-quarter results to continued momentum from Fanapt and an early contribution from NEREUS, whose commercial launch had recently begun. HETLIOZ and PONVORY also contributed to revenue.